{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T00:13:03Z","timestamp":1789776783057,"version":"4.0.1"},"reference-count":52,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014480","name":"Horizon Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology and Allergy Clinics of North America"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.iac.2025.01.004","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T20:36:07Z","timestamp":1741725367000},"page":"287-298","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Non-Infectious Complications of Chronic Granulomatous Disease"],"prefix":"10.1016","volume":"45","author":[{"given":"Christopher","family":"McKinney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Ambruso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.iac.2025.01.004_bib1","series-title":"Kendig\u2019s Disorders of the Respiratory Tract in Children","first-page":"909","article-title":"63 - Primary immunodeficiency and other diseases with immune dysregulation","author":"Ambruso","year":"2019"},{"issue":"3","key":"10.1016\/j.iac.2025.01.004_bib2","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1097\/00005792-200005000-00003","article-title":"Chronic granulomatous disease. Report on a national registry of 368 patients","volume":"79","author":"Winkelstein","year":"2000","journal-title":"Medicine (Baltim)"},{"issue":"27","key":"10.1016\/j.iac.2025.01.004_bib3","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1056\/NEJMoa1007097","article-title":"Residual NADPH oxidase and survival in chronic granulomatous disease","volume":"363","author":"Kuhns","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.iac.2025.01.004_bib4","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/252460","article-title":"Current concepts of hyperinflammation in chronic granulomatous disease","volume":"2012","author":"Rieber","year":"2012","journal-title":"Clin Dev Immunol"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib5","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/cid\/ciw837","article-title":"Chronic granulomatous disease in patients reaching adulthood: a nationwide study in France","volume":"64","author":"Dunogue","year":"2017","journal-title":"Clin Infect Dis"},{"issue":"4","key":"10.1016\/j.iac.2025.01.004_bib6","article-title":"Inflammatory complications in chronic granulomatous disease","volume":"13","author":"Grammatikos","year":"2024","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.iac.2025.01.004_bib7","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1110115","article-title":"Granulomatous inflammation in inborn errors of immunity","volume":"11","author":"Sacco","year":"2023","journal-title":"Front Pediatr"},{"issue":"5","key":"10.1016\/j.iac.2025.01.004_bib8","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1016\/j.jaip.2021.12.035","article-title":"Chronic granulomatous disease with inflammatory bowel disease: clinical presentation, treatment, and outcomes from the USIDNET registry","volume":"10","author":"LaBere","year":"2022","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.iac.2025.01.004_bib9","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/jgh.16342","article-title":"Small bowel disease prevalence on video capsule endoscopy in chronic granulomatous disease-associated inflammatory bowel disease","volume":"38","author":"Bhattacharya","year":"2023","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib10","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1183\/09031936.00118414","article-title":"Pulmonary manifestations in adult patients with chronic granulomatous disease","volume":"45","author":"Salvator","year":"2015","journal-title":"Eur Respir J"},{"issue":"8","key":"10.1016\/j.iac.2025.01.004_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1001\/jamadermatol.2024.1393","article-title":"Cutaneous inflammatory manifestations of chronic granulomatous disease","volume":"160","author":"Dev","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.iac.2025.01.004_bib12","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2249.2008.03644.x","article-title":"Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry","volume":"152","author":"Jones","year":"2008","journal-title":"Clin Exp Immunol"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib13","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaci.2008.07.050","article-title":"Chronic granulomatous disease as a risk factor for autoimmune disease","volume":"122","author":"De Ravin","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.iac.2025.01.004_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2017.02.029","article-title":"Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom","volume":"140","author":"Battersby","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.iac.2025.01.004_bib15","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","article-title":"X-linked carriers of chronic granulomatous disease: illness, lyonization, and stability","volume":"141","author":"Marciano","year":"2018","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.iac.2025.01.004_bib16","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1084\/jem.20161382","article-title":"Eros is a novel transmembrane protein that controls the phagocyte respiratory burst and is essential for innate immunity","volume":"214","author":"Thomas","year":"2017","journal-title":"J\u00a0Exp Med"},{"issue":"suppl_1","key":"10.1016\/j.iac.2025.01.004_bib17","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1093\/jpids\/piy008","article-title":"Chronic granulomatous disease: epidemiology, pathophysiology, and genetic basis of disease","volume":"7","author":"Rider","year":"2018","journal-title":"J\u00a0Pediatric Infect Dis Soc"},{"issue":"3","key":"10.1016\/j.iac.2025.01.004_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.jaci.2014.04.014","article-title":"Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease","volume":"134","author":"Magnani","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"11","key":"10.1016\/j.iac.2025.01.004_bib19","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s00467-014-2883-7","article-title":"How should eosinophilic cystitis be treated in patients with chronic granulomatous disease?","volume":"29","author":"Claps","year":"2014","journal-title":"Pediatr Nephrol"},{"issue":"3","key":"10.1016\/j.iac.2025.01.004_bib20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2141.2007.06880.x","article-title":"Modern management of chronic granulomatous disease","volume":"140","author":"Seger","year":"2008","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.iac.2025.01.004_bib21","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1590\/1414-431X20143735","article-title":"Chronic granulomatous disease: why an inflammatory disease?","volume":"47","author":"Roxo-Junior","year":"2014","journal-title":"Braz J Med Biol Res"},{"issue":"1","key":"10.1016\/j.iac.2025.01.004_bib22","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.clim.2008.06.005","article-title":"ROS-deficient monocytes have aberrant gene expression that correlates with inflammatory disorders of chronic granulomatous disease","volume":"129","author":"Brown","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.iac.2025.01.004_bib23","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.3389\/fimmu.2019.02236","article-title":"High Levels of IL-18 and IFN-gamma in chronically inflamed tissue in chronic granulomatous disease","volume":"10","author":"Meda Spaccamela","year":"2019","journal-title":"Front Immunol"},{"issue":"7175","key":"10.1016\/j.iac.2025.01.004_bib24","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1038\/nature06471","article-title":"Defective tryptophan catabolism underlies inflammation in mouse chronic granulomatous disease","volume":"451","author":"Romani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.iac.2025.01.004_bib25","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40168-016-0159-0","article-title":"Colitis susceptibility in p47(phox-\/-) mice is mediated by the microbiome","volume":"4","author":"Falcone","year":"2016","journal-title":"Microbiome"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib26","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1038\/s41385-019-0205-x","article-title":"Colitis susceptibility in mice with reactive oxygen species deficiency is mediated by mucus barrier and immune defense defects","volume":"12","author":"Aviello","year":"2019","journal-title":"Mucosal Immunol"},{"issue":"4","key":"10.1016\/j.iac.2025.01.004_bib27","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1002\/eji.200737348","article-title":"Th17 development and autoimmune arthritis in the absence of reactive oxygen species","volume":"38","author":"George-Chandy","year":"2008","journal-title":"Eur J Immunol"},{"issue":"12","key":"10.1016\/j.iac.2025.01.004_bib28","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1097\/MIB.0000000000000966","article-title":"Genetic risk for inflammatory bowel disease is a determinant of crohn\u2019s disease development in chronic granulomatous disease","volume":"22","author":"Huang","year":"2016","journal-title":"Inflamm Bowel Dis"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib29","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1016\/j.jaci.2023.07.022","article-title":"Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease","volume":"152","author":"Chandrasekaran","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"9","key":"10.1016\/j.iac.2025.01.004_bib30","doi-asserted-by":"crossref","first-page":"3526","DOI":"10.1073\/pnas.1322831111","article-title":"IL-1 receptor blockade restores autophagy and reduces inflammation in chronic granulomatous disease in mice and in humans","volume":"111","author":"de Luca","year":"2014","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"issue":"5","key":"10.1016\/j.iac.2025.01.004_bib31","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1189\/jlb.1202599","article-title":"Diminished production of anti-inflammatory mediators during neutrophil apoptosis and macrophage phagocytosis in chronic granulomatous disease (CGD)","volume":"73","author":"Brown","year":"2003","journal-title":"J\u00a0Leukoc Biol"},{"issue":"2","key":"10.1016\/j.iac.2025.01.004_bib32","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/rheumatology\/kei135","article-title":"Abnormal apoptosis in chronic granulomatous disease and autoantibody production characteristic of lupus","volume":"45","author":"Sanford","year":"2006","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.iac.2025.01.004_bib33","doi-asserted-by":"crossref","first-page":"C621","DOI":"10.1152\/ajpcell.00651.2008","article-title":"Involvement of a functional NADPH oxidase in neutrophils and macrophages during programmed cell clearance: implications for chronic granulomatous disease","volume":"297","author":"Sanmun","year":"2009","journal-title":"Am J Physiol Cell Physiol"},{"issue":"5","key":"10.1016\/j.iac.2025.01.004_bib34","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jaci.2015.07.034","article-title":"Impaired efferocytosis in human chronic granulomatous disease is reversed by pioglitazone treatment","volume":"136","author":"Fernandez-Boyanapalli","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.iac.2025.01.004_bib35","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0022-3476(87)80452-3","article-title":"Corticosteroids in treatment of obstructive lesions of chronic granulomatous disease","volume":"111","author":"Chin","year":"1987","journal-title":"J\u00a0Pediatr"},{"issue":"2","key":"10.1016\/j.iac.2025.01.004_bib36","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1542\/peds.114.2.462","article-title":"Gastrointestinal involvement in chronic granulomatous disease","volume":"114","author":"Marciano","year":"2004","journal-title":"Pediatrics"},{"issue":"4","key":"10.1016\/j.iac.2025.01.004_bib37","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.jaci.2013.04.059","article-title":"Efficacy and safety of thalidomide in patients with inflammatory manifestations of chronic granulomatous disease: a retrospective case series","volume":"132","author":"Noel","year":"2013","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.iac.2025.01.004_bib38","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.jaip.2022.12.039","article-title":"Gastrointestinal and hepatic manifestations of chronic granulomatous disease","volume":"11","author":"Yang","year":"2023","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib39","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/ajg.2015.135","article-title":"Treatment with anakinra, a recombinant IL-1 receptor antagonist, unlikely to induce lasting remission in patients with CGD Colitis","volume":"110","author":"Hahn","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"12","key":"10.1016\/j.iac.2025.01.004_bib40","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1086\/657308","article-title":"Complications of tumor necrosis factor-alpha blockade in chronic granulomatous disease-related colitis","volume":"51","author":"Uzel","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"6","key":"10.1016\/j.iac.2025.01.004_bib41","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1016\/j.jaip.2017.07.035","article-title":"Treatment of chronic granulomatous disease-associated fistulising colitis with vedolizumab","volume":"5","author":"Campbell","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.iac.2025.01.004_bib42","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1093\/gastro\/goaa005","article-title":"The response to vedolizumab in chronic granulomatous disease-related inflammatory bowel disease","volume":"8","author":"Kamal","year":"2020","journal-title":"Gastroenterol Rep (Oxf)"},{"issue":"9","key":"10.1016\/j.iac.2025.01.004_bib43","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/ibd\/izz006","article-title":"Efficacy of combination antibiotic therapy for refractory pediatric inflammatory bowel disease","volume":"25","author":"Breton","year":"2019","journal-title":"Inflamm Bowel Dis"},{"issue":"2","key":"10.1016\/j.iac.2025.01.004_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263370","article-title":"In\u00a0vivo interferon-gamma induced changes in gene expression dramatically alter neutrophil phenotype","volume":"17","author":"Ambruso","year":"2022","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.iac.2025.01.004_bib45","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.4049\/jimmunol.1001778","article-title":"Impaired phagocytosis of apoptotic cells by macrophages in chronic granulomatous disease is reversed by IFN-gamma in a nitric oxide-dependent manner","volume":"185","author":"Fernandez-Boyanapalli","year":"2010","journal-title":"J\u00a0Immunol"},{"issue":"3","key":"10.1016\/j.iac.2025.01.004_bib46","doi-asserted-by":"crossref","first-page":"4321","DOI":"10.1002\/jcb.27718","article-title":"Gene expression in chronic granulomatous disease and interferon-gamma receptor-deficient cells treated in\u00a0vitro with interferon-gamma","volume":"120","author":"Frazao","year":"2019","journal-title":"J\u00a0Cell Biochem"},{"issue":"5","key":"10.1016\/j.iac.2025.01.004_bib47","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1086\/422993","article-title":"Long-term interferon-gamma therapy for patients with chronic granulomatous disease","volume":"39","author":"Marciano","year":"2004","journal-title":"Clin Infect Dis"},{"issue":"8","key":"10.1016\/j.iac.2025.01.004_bib48","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJM199102213240801","article-title":"A\u00a0controlled trial of interferon gamma to prevent infection in chronic granulomatous disease","volume":"324","author":"International Chronic Granulomatous Disease Cooperative Study G","year":"1991","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.iac.2025.01.004_bib49","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s10875-019-00659-8","article-title":"Chronic granulomatous disease-associated IBD resolves and does not adversely impact survival following allogeneic HCT","volume":"39","author":"Marsh","year":"2019","journal-title":"J\u00a0Clin Immunol"},{"issue":"10","key":"10.1016\/j.iac.2025.01.004_bib50","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.iac.2025.01.004_bib51","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/blood.2022019586","article-title":"Genotype, oxidase status, and preceding infection or autoinflammation do not affect allogeneic HCT outcomes for CGD","volume":"142","author":"Leiding","year":"2023","journal-title":"Blood"},{"issue":"suppl_1","key":"10.1016\/j.iac.2025.01.004_bib52","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/jpids\/piy011","article-title":"Future of care for patients with chronic granulomatous disease: gene therapy and targeted molecular medicine","volume":"7","author":"Keller","year":"2018","journal-title":"J\u00a0Pediatric Infect Dis Soc"}],"container-title":["Immunology and Allergy Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856125000049?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889856125000049?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T07:04:45Z","timestamp":1745564685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889856125000049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":52,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S0889856125000049"],"URL":"https:\/\/doi.org\/10.1016\/j.iac.2025.01.004","relation":{},"ISSN":["0889-8561"],"issn-type":[{"value":"0889-8561","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Non-Infectious Complications of Chronic Granulomatous Disease","name":"articletitle","label":"Article Title"},{"value":"Immunology and Allergy Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iac.2025.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}